|
| U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Add-On Treatment to Lithium or Valproate in ... |
8 May 08, 21:13 |
|
| Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) approved updated labeling for ABILIFY(R) (aripiprazole) as an adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in adults. |
| more |
|
